LY-320,135
LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB 1 .
≈ 1 min read
LY-320,135. encyclopegia.org, snapshot enwiki-001341436302. /a/ly-320-135
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB 1 . It was developed by Eli Lilly and Company in the 1990s.
LY-320,135 displays fairly good selectivity, with a binding affinity for CB 1 around 70x stronger than for CB 2 , but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB 1 antagonists act as inverse agonists at higher doses.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1341436302 under CC BY-SA 4.0; modifications have been made.